Aura buying assisted living chain Bait Bakfar

Aura Investments (TASE: AURA) is acquiring a 55% stake in Bait Bakfar (TASE: BKFR) for NIS 935 million, valuing the assisted living chain at NIS 1.7 billion. Aura plans a tender offer for the remaining shares, with a 28% premium over BKFR's current share price. The deal includes cash and Aura shares, valuing Aura at NIS 5.5 billion.

Original reporting
Published Oct 26, 2026, 10:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aura buying assisted living chain Bait Bakfar — source image
Decision brief

The 30-second read

$AURABullishHigh
01

Why it matters

The disclosed consideration structure (cash plus AURA shares valued at NIS 5.5b) and the stated 28% premium create a clear valuation anchor for both AURA and BKFR, making the announcement tradable via takeover-spread dynamics.

02

Market read

A disclosed controlling-stake purchase plus a tender offer at a stated premium is a direct, tradable catalyst for takeover-spread positioning in both the acquirer and target.

03

What to watch

Execution details not covered here, such as regulatory approvals, tender acceptance thresholds, and financing or share-issuance mechanics, could materially affect the spread and timing.

Relevance 9/10Novelty 9/10Timing: today, deal announcement with tender offer premium and consideration mix

Background

Aura Investments, controlled by Yaacov Atrakchi, is acquiring assisted-living operator Bait Bakfar, including a controlling-stake purchase and a follow-on tender for minority holders.

Company-level read

Ticker impact

$AURABullishMedium confidence
Context

Aura Investments agreed to buy a 55% controlling stake in Bait Bakfar for NIS 935m and launch a tender offer for the rest at a 28% premium.

Expected impact

Likely upward bias as markets price the tender premium and deal completion probability.

Evidence & confidence

The article discloses cash purchase, tender structure, and implied valuation for AURA shares used in the offer, which can drive near-term sentiment and spread dynamics.

Market effects

Could increase deal activity and valuation expectations for Israeli assisted-living operators and real-estate healthcare-adjacent assets.

May concentrate capital in the Israeli senior-care real-estate segment and shift investor focus toward consolidation plays.

Limited, as the transaction is localized to Israel’s TASE-listed issuers.

Counterpoint

Tender offers with equity consideration can introduce dilution/valuation uncertainty for the acquirer, and deal completion risk can cap the target’s upside.

Key entities

  • Aura Investments

    TASE-listed acquirer (TASE: AURA) planning to buy 55% of Bait Bakfar and launch a tender offer for the remainder.

  • Bait Bakfar

    TASE-listed assisted living chain (TASE: BKFR) targeted for acquisition, with a tender offer implying a 28% premium.

  • Blustein family

    Controlling shareholders of Bait Bakfar selling their shares for NIS 935m in cash.

  • Poalim Equity

    Holds 18% of Bait Bakfar and is included in the tender offer.

  • More Investment House

    Holds 8% of Bait Bakfar and is included in the tender offer.

Related articles

$AURAMedAI 8/10

Aura Biosciences 3Q 2026: EPS ($0.29) — 10-Q Summary

Aura Biosciences reported a wider net loss in Q3 2026, with increased R&D and G&A expenses offsetting higher interest income. The loss per share narrowed to $0.29. The CoMpass trial enrollment is complete, and topline data is expected in 2H 2027. The company also reported interim data for NMIBC treatment and completed a restructuring.

$CRMDHighAI 8/10

CorMedix stock maintains outperform rating on Heron acquisition

Citizens reiterated an Outperform rating and $19.00 price target on CorMedix (CRMD). The company agreed to acquire Heron Therapeutics' assets for $225M, expecting to close in Q1 2027. CRMD reported Q2 2026 earnings of $0.29/share on $101.9M revenue, beating estimates. Analysts highlight strategic fit, revenue diversification, and strong financials.